A Randomised, Single Dose, 5-period, 5-treatment, Crossover Study to Assess the Relative Bioavailability of 4 Different Formulations of Verinurad and Allopurinol in Healthy Subjects

This study is a single centre, randomised, open-label, single-dose, 5-period, 5-treatment, crossover study in healthy male and female subjects. This study is intended to assess the relative bioavailability between the fixed dose combination (FDC, i.e. verinurad/allopurinol FDC capsule 12/300 mg) and free combination formulations of verinurad (i.e. verinurad prolonged release Hydroxypropyl methylcellulose [HPMC] capsule 12 mg) and allopurinol (i.e. allopurinol table 300 mg) in fasted and fed conditions. The study will also assess the relative bioavailability between a formulation only containing verinurad (i.e. verinurad prolonged release gelatin capsule 12 mg) and the FDC capsule.

开始日期2021-04-13

申办/合作机构

AstraZeneca PLC

[+1]

NCT04532918

/ Completed临床1期

An Open-label, 3-Treatment, 3-Period, Fixed Sequence Study in Healthy Subjects to Assess the Pharmacokinetics of Verinurad and Allopurinol When Administered Alone, and in Combination With Single Doses of Cyclosporine or Rifampicin

This Phase 1 study aims to quantify the effects of cyclosporine, a broad transporter inhibitor, and rifampicin, an OATP1B1/3 inhibitor, on verinurad pharmacokinetics (PK). The study is conducted in accordance with Food and Drug Administration guidance on Clinical Drug Interaction Studies, 2020. Verinurad will be developed as a fixed combination since it will always be administered together with allopurinol.

开始日期2020-09-10

申办/合作机构

AstraZeneca PLC

[+1]

NCT04327024

/ Completed临床2期

A Phase 2, Multicentre, Double-Blind, Placebo and Active Control Efficacy and Safety Study to Evaluate Verinurad Combined With Allopurinol in Heart Failure With Preserved Ejection Fraction

International, Multicenter, Double-Blind, Placebo and Active Control Efficacy and Safety Study to Evaluate Verinurad combined with Allopurinol in Heart Failure with Preserved Ejection Fraction

开始日期2020-05-19

申办/合作机构

AstraZeneca PLC

100 项与 Verinurad 相关的临床结果

登录后查看更多信息

100 项与 Verinurad 相关的转化医学

登录后查看更多信息

100 项与 Verinurad 相关的专利（医药）

登录后查看更多信息

项与 Verinurad 相关的文献（医药）

2025-03-24·JACS Au

Structural Basis for Inhibition of Urate Reabsorption in URAT1

Article

作者: Bai, Yingjie ; Guo, Nianxin ; Fan, Junping ; Lei, Xiaoguang ; Ke, Han ; Wang, Haijun ; Zhang, Jing ; Xie, Wenjun ; Wang, Jin

The urate transporter 1 (URAT1) is the primary urate transporter in the kidney responsible for urate reabsorption and, therefore, is crucial for urate homeostasis. Hyperuricemia causes the common human disease gout and other pathological consequences. Inhibition of urate reabsorption through URAT1 has been shown as a promising strategy in alleviating hyperuricemia, and clinical and preclinical drug candidates targeting URAT1 are emerging. However, how small molecules inhibit URAT1 remains undefined, and the lack of accurate URAT1 complex structures hinders the development of better therapeutics. Here, we present cryoelectron microscopy structures of a humanized rat URAT1 bound with benzbromarone, lingdolinurad, and verinurad, elucidating the structural basis for drug recognition and inhibition. The three small molecules reside in the URAT1 central cavity with different binding modes, locking URAT1 in an inward-facing conformation. This study provides mechanistic insights into the drug modulation of URAT1 and sheds light on the rational design of potential URAT1-specific therapeutics for treating hyperuricemia.

2024-10-01·JAMA Cardiology

Verinurad Plus Allopurinol for Heart Failure With Preserved Ejection Fraction

Article

作者: Kitzman, Dalane W. ; Mentz, Robert J. ; Sjöström, C. David ; Voors, Adriaan A. ; Shah, Sanjiv J. ; Källgren, Christian ; Myte, Robin ; Perl, Shira ; Lewis, Gregory D. ; Kaguthi, Grace

Importance:

Elevated serum uric acid (SUA) level may contribute to endothelial dysfunction; therefore, SUA is an attractive target for heart failure with preserved ejection fraction (HFpEF). However, to the authors’ knowledge, no prior randomized clinical trials have evaluated SUA lowering in HFpEF.

Objective:

To investigate the efficacy and safety of the novel urate transporter–1 inhibitor, verinurad, in patients with HFpEF and elevated SUA level.

Design, Setting, and Participants:

This was a phase 2, double-blind, randomized clinical trial (32-week duration) conducted from May 2020 to April 2022. The study took place at 59 centers in 12 countries and included patients 40 years and older with HFpEF and SUA level greater than 6 mg/dL. Data were analyzed from August 2022 to May 2024.

Interventions:

Eligible patients were randomized 1:1:1 to once-daily, oral verinurad, 12 mg, plus allopurinol, 300 mg; allopurinol, 300 mg, monotherapy; or placebo for 24 weeks after an 8-week titration period. Allopurinol was combined with verinurad to prevent verinurad-induced urate nephropathy, and the allopurinol monotherapy group was included to account for allopurinol effects in the combination therapy group. All patients received oral colchicine, 0.5 to 0.6 mg, daily for the first 12 weeks after randomization.

Main Outcomes and Measures:

Key end points included changes from baseline to week 32 in peak oxygen uptake (VO2), Kansas City Cardiomyopathy Questionnaire total symptom score (KCCQ-TSS), and SUA level; and safety/tolerability (including adjudicated cardiovascular events).

Results:

Among 159 randomized patients (53 per treatment group; median [IQR] age, 71 [40-86] years; 103 male [65%]) with median (IQR) N-terminal pro–brain natriuretic peptide level of 527 (239-1044) pg/mL and SUA level of 7.5 (6.6-8.4) mg/dL, verinurad plus allopurinol (mean change, −59.6%; 95% CI, −64.4% to −54.2%) lowered SUA level to a greater extent than allopurinol (mean change, −37.6%; 95% CI, −45.3% to −28.9%) or placebo (mean change, 0.8%; 95% CI, −11.8% to 15.2%; P &lt; .001). Changes in peak VO2 (verinurad plus allopurinol, 0.27 mL/kg/min; 95% CI, −0.56 to 1.10 mL/kg/min; allopurinol, −0.17 mL/kg/min; 95% CI, −1.03 to 0.69 mL/kg/min; placebo, 0.37 mL/kg/min; 95% CI, −0.45 to 1.19 mL/kg/min) and KCCQ-TSS (verinurad plus allopurinol, 4.3; 95% CI, 0.3-8.3; allopurinol, 4.5; 95% CI, 0.3-8.6; placebo, 1.2; 95% CI, −3.0 to 5.3) were similar across groups. There were no adverse safety signals. Deaths or cardiovascular events occurred in 3 patients (5.7%) in the verinurad plus allopurinol group, 8 patients (15.1%) in the allopurinol monotherapy group, and 6 patients (11.3%) in the placebo group.

Conclusions and Relevance:

Results of this randomized clinical trial show that despite substantial SUA lowering, verinurad plus allopurinol did not result in a significant improvement in peak VO2 or symptoms compared with allopurinol monotherapy or placebo in HFpEF.

Trial Registration:

ClinicalTrials.gov Identifier: NCT04327024

2024-05-01·Journal of the American Society of Nephrology : JASN

Combination Treatment with Verinurad and Allopurinol in CKD

Article

作者: Perl, Shira ; Bjursell, Magnus ; Rikte, Tord ; Stack, Austin G. ; Perkovic, Vlado ; Inker, Lesley A. ; Maklad, Noha ; Heerspink, Hiddo J.L. ; Sjöström, C. David ; Jongs, Niels ; Terkeltaub, Robert ; Eklund, Olof

Key Points:

The SAPPHIRE trial was designed to assess albuminuria-lowering effects of the urate transporter 1 inhibitor verinurad combined with allopurinol in patients with CKD.Verinurad 3, 7.5, and 12 mg in combination with allopurinol 300 mg did not reduce albuminuria during 34 weeks treatment compared with allopurinol alone or placebo.Verinurad/allopurinol combination dose-dependently reduced serum urate concentrations compared with placebo.

Background:

Hyperuricemia is associated with elevated risks of cardiovascular and chronic kidney disease (CKD). Since inhibition of urate transporter 1 has been suggested to be potentially nephroprotective, we performed a phase 2b study to assess albuminuria-lowering effects of the urate transporter 1 inhibitor verinurad combined with the xanthine oxidase inhibitor allopurinol in patients with CKD and hyperuricemia.

Methods:

In this randomized placebo and active controlled trial, we enrolled participants with serum urate concentrations ≥6.0 mg/dl, eGFR ≥25 ml/min per 1.73 m2, and a urinary albumin-creatinine ratio (UACR) 30–5000 mg/g to one of five treatment arms: placebo, placebo+allopurinol 300 mg/day, verinurad 3 mg+allopurinol 300 mg/day, verinurad 7.5 mg+allopurinol 300 mg/day, or verinurad 12 mg+allopurinol 300 mg/day in a 1:1:1:1:1 ratio. The primary end point was the change in UACR from baseline to 34 weeks. Secondary end points were changes from baseline in UACR at week 60 and changes in serum urate and eGFR at weeks 34 and 60.

Results:

Between August 2019 and November 2021, 861 adults with CKD (mean age 65 years, 33.0% female, mean eGFR 48 ml/min per 1.73 m2, median UACR 217 mg/g) were enrolled. At 34 weeks, the geometric mean percentage change in UACR from baseline did not differ among treatment groups (16.7%, 95% confidence interval [CI], −0.6 to 37.1 in the 3 mg group, 15.0% [95% CI, −1.85 to 34.6] in the 7.5 mg group, 14.0% [95% CI, −3.4 to 34.4] in the 12 mg group versus 9.9% [95% CI, −6.6 to 29.4] in the allopurinol group, and 37.3% [95% CI, 16.6 to 61.8] in the placebo group). UACR and eGFR change from baseline did not differ among treatment groups after 60 weeks. Verinurad/allopurinol combination dose-dependently reduced serum urate concentrations compared with placebo. The proportion of patients with adverse events and serious adverse events was balanced among treatment groups.

Conclusions:

Verinurad in combination with allopurinol did not decrease UACR or eGFR decline, but further reduced serum urate compared with allopurinol alone or placebo.

Clinical Trial registry name and registration number::

SAPPHIRE Trial registration number, NCT03990363.

项与 Verinurad 相关的新闻（医药）

2021-11-12

·Endpoints

AstraZeneca expects 'modest profitability' for next round of Covid-19 vaccine supply deals — and prunes pipeline in Q3 update

Having sent 1.5 billion Covid-19 vaccines around the world on a not-for-profit basis, AstraZeneca says it’s time to move into “modest profitability.” While the priority is to deliver all the “pandemic doses” — a total of 3 billion are set to be delivered by the end of the year — AstraZeneca expects to be taking new orders in Q4, leading to a blend in sales. “Don’t expect massive profitability, which is sometimes the case for other vaccine makers,” Ruud Dobber, head of the biopharmaceuticals business unit, told Endpoints News . Mene Pangalos, his counterpart on the R&D side, added that low-income countries will still be able to get the vaccine, whether as the primary series or a booster, at the not-for-profit price under its tiered pricing arrangements. The pivot, which has been teased in previous comments, is among multiple updates disclosed in the company’s Q3 earnings report. AstraZeneca also noted those expected profits will offset costs of its long-acting antibody program, which is being reviewed by several regulatory agencies. Despite coming late in the race, Pangalos believes antibody will play a big role by filling the gap between vaccines and treatments like oral antivirals. “Others are talking about prophylaxis, but they’re talking about monthly administration, we’re talking about, potentially, at a maximum twice a year. I’m hoping it’ll be once a year,” he said, adding in the treatment setting, “you won’t just be treated for the two weeks that you’ve got the symptoms, you’ll be treated the next 12 months in terms of prevention. I know what I would take.” As is custom for these seasonal announcements, AstraZeneca also revealed some pruning of the pipeline. The team is dropping two Phase II combo trials anchored by its PD-L1 Imfinzi: One had tested Imfinzi together with MEDI0457, a DNA HPV vaccine, in head and neck squamous cell carcinoma. The other involved chemotherapy and imaradenant — which it had licensed from Sosei Heptares in 2015. Its removal, according to Sosei Heptares, may mean the drug is returning where it came from. Finally, out goes verinurad, the URAT1 inhibitor that was being tested for chronic kidney disease and heart failure with a preserved ejection fraction, which Pangalos said just didn’t look as good as everything else in the pipeline. “Post Alexion acquisition, we’ve spent a lot of time reviewing all of the opportunities,” Pangalos said. “We have the scientific merits, the business cases, the revenues, the timing, and obviously, you know, wanting to be disciplined in terms of R&D spend, which is already being pushed to the limit, because the opportunities that we have, we had to deprioritize certain assets.” Here’s some of those programs they are prioritizing and ushering into Phase I and II:

疫苗抗体并购

2021-04-23

·BioSpace

Uric Acid Drugs Market: Rise in the incidence and prevalence of gout and other related disorders to drive the market

Uric acid is produced in the body after the metabolic breakdown of purine nucleotides. An excess uric acid in the body leads to a chronic inflammatory condition known as gout. An excess of uric acid leads to the formation of crystals in the body, which eventually leads to the deposition of uric acid crystals in joints, resulting in inflammation and pain. Read Report Overview - It also leads to other medical condition such as diabetes, kidney stones, hyperparathyroidism, bone marrow disorders, and others. Excess uric acid leads to swollen joints, pain, heat, redness, and joint stiffness. Symptoms start with the inflammation of the big toe. However, an excess of uric acid can affect several joints of the body such as ankles, fingers, heels, wrists, knees, and elbows. Symptoms are more prevalent in men compared to women. Problems due to uric acid are more prevalent in developed countries as compares to other parts of the world. In 2013, uric acid problems affected around 5.8 million people, or about 1%-2% of the total population in the western world. Request Brochure of Uric Acid Drugs Market Report - The global uric acid drugs market can be segmented based on drug, distribution channel, and geography. Based on drug, the global uric acid drugs market can be classified into allopurinol, febuxostat, and probenecid. In terms of distribution channel, the uric acid drugs market can be categorized into online pharmacies, retail pharmacies, and hospital pharmacies. The hospital pharmacies and retail pharmacies segments are expected to hold a key share of the uric acid drugs market, due an increase in the number of hospital visits and stays. The online pharmacies segment is anticipated to expand at a high CAGR during forecast period, due a rise in the number of Internet users and ease of use of these pharmacies. Request for Analysis of COVID-19 Impact on Uric Acid Drugs Market – Rise in the incidence and prevalence of gout and other related disorders, increased research and development expenditure, and growing awareness among people are projected to boost the global uric acid drugs market in the coming years. Moreover, there is a strong ongoing clinical pipeline of drugs that reduce uric acid levels in the body. For instance, SEL 212 by Selecta Biosciences, verinurad by Ardea Biosciences, URC-102 by JW Pharmaceutical, and others. This is likely to further drive the uric acid drugs market during the forecast period. However, sideeffects associated with current treatment and disappointing results of promising pipeline molecules are expected to hamper the global uric acid drugs market during the forecast period. Pre-book Uric Acid Drugs Market Report -

100 项与 Verinurad 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11129	-	-	DB11873

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
射血分数保留型心力衰竭	临床2期	美国	AstraZeneca PLC	2020-05-19
射血分数保留型心力衰竭	临床2期	阿根廷	AstraZeneca PLC	2020-05-19
射血分数保留型心力衰竭	临床2期	澳大利亚	AstraZeneca PLC	2020-05-19
射血分数保留型心力衰竭	临床2期	奥地利	AstraZeneca PLC	2020-05-19
射血分数保留型心力衰竭	临床2期	保加利亚	AstraZeneca PLC	2020-05-19
射血分数保留型心力衰竭	临床2期	加拿大	AstraZeneca PLC	2020-05-19
射血分数保留型心力衰竭	临床2期	德国	AstraZeneca PLC	2020-05-19
射血分数保留型心力衰竭	临床2期	墨西哥	AstraZeneca PLC	2020-05-19
射血分数保留型心力衰竭	临床2期	波兰	AstraZeneca PLC	2020-05-19
射血分数保留型心力衰竭	临床2期	俄罗斯	AstraZeneca PLC	2020-05-19

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04327024 (AMETHYST, Pubmed \| JAMA Cardiol) 人工标引	临床2期	射血分数保留型心力衰竭	159	Verinurad plus Allopurinol	窪顧鬱顧餘製齋衊選顧(網築選鹹鏇襯窪鑰願衊) = 蓋衊襯製糧鏇窪鑰範蓋鑰願鑰鹹鬱築夢選網壓 (鹹範壓構網齋襯網窪積, -0.56 ~ 1.10) 更多	不佳	2024-08-14
				Allopurinol	窪顧鬱顧餘製齋衊選顧(網築選鹹鏇襯窪鑰願衊) = 繭繭壓簾顧艱願醖遞窪鑰願鑰鹹鬱築夢選網壓 (鹹範壓構網齋襯網窪積, -1.03 ~ 0.69) 更多
NCT04327024 (AMETHYST, CTgov)	临床2期	射血分数保留型心力衰竭	159	Placebo for verinurad	餘廠壓艱膚鏇壓鏇獵衊(鑰製鏇醖選築齋衊夢醖) = 構觸積遞襯繭夢艱範願獵簾壓範鹹遞觸蓋築築 (廠範鏇鹽糧鏇糧鹽觸窪, 襯憲觸壓襯淵鏇獵鹹蓋 ~ 觸網願糧襯鑰製鹽簾醖) 更多	-	2023-06-29
NCT04550234 (CTgov)	临床1期	慢性肾病	25	Verinurad prolonged release HPMC capsule+Allopurinol Tablet (Treatment 1)	選壓繭憲繭蓋獵鑰憲醖(簾鏇鏇膚鹹觸膚窪鬱鹹) = 鏇簾製鹹簾簾鹽齋夢衊壓製糧遞遞構鏇衊鏇蓋 (觸蓋廠鹽淵窪齋齋鏇願, 48.87) 更多	-	2023-05-10
				Verinurad+Allopurinol (Treatment 2)	選壓繭憲繭蓋獵鑰憲醖(簾鏇鏇膚鹹觸膚窪鬱鹹) = 鑰艱範窪遞構獵廠窪積壓製糧遞遞構鏇衊鏇蓋 (觸蓋廠鹽淵窪齋齋鏇願, 48.63) 更多
NCT04532918 (CTgov)	临床1期	慢性肾病	14	Verinurad+Allopurinol (Period 1: Verinurad + Allopurinol)	繭顧蓋淵醖製繭夢願齋(築積築齋憲鏇夢網齋窪) = 齋繭鑰糧餘遞觸範艱襯簾簾獵鑰窪膚範憲鏇顧 (鑰範網積鏇廠廠獵築糧, 53.48) 更多	-	2023-03-27
				Verinurad+Cyclosporine+Allopurinol (Period 2: Verinurad + Allopurinol + Cyclosporine)	繭顧蓋淵醖製繭夢願齋(築積築齋憲鏇夢網齋窪) = 簾鑰獵齋獵窪顧鬱築鹹簾簾獵鑰窪膚範憲鏇顧 (鑰範網積鏇廠廠獵築糧, 29.39) 更多
NCT04256629 (Pubmed \| Br J Clin Pharmacol)	临床1期	慢性肾病	24	Verinurad 24 mg extended release + allopurinol 300 mg	壓選簾鬱夢選夢顧艱艱(鏇衊夢鬱廠顧壓壓醖鬱) = 積簾艱憲顧簾餘顧膚齋鹹衊鏇鑰網淵衊構鏇顧 (衊壓齋範構鑰簾鬱鑰繭, -4.6, ~ 0.8)	-	2022-12-12
NCT04256629 (CTgov)	临床1期	慢性肾病	24	ER8+verinurad+allopurinol (Treatment A)	艱鑰築鏇積糧淵選廠鏇(構積憲觸襯鹹構夢鹽獵) = 製醖憲獵鏇鏇醖襯鑰蓋選膚衊觸繭淵醖鑰蓋積 (獵願鹽鹽艱艱簾衊窪鏇, 積淵範夢齋鑰鏇醖艱願 ~ 衊簾觸襯壓膚選壓憲醖) 更多	-	2022-01-31
				verinurad+allopurinol (Treatment B)	艱鑰築鏇積糧淵選廠鏇(構積憲觸襯鹹構夢鹽獵) = 鏇觸鹹窪膚廠繭獵願膚選膚衊觸繭淵醖鑰蓋積 (獵願鹽鹽艱艱簾衊窪鏇, 選衊獵壓顧憲網簾範鹽 ~ 鑰衊遞獵範觸壓壓醖顧) 更多
NCT03316131 (Pubmed \| J Clin Endocrinol Metab) 人工标引	临床2期	高尿酸血症	36	verinurad+febuxostat+dapagliflozin	窪簾積糧製鏇壓襯膚壓(獵願醖築顧繭簾構鹽鑰) = 遞鏇襯廠糧遞襯膚窪襯範簾醖糧鑰窪遞顧範艱 (鬱鏇獵範廠襯齋網醖製, -21.0 ~ -4.7) 更多	积极	2021-04-23
				Placebo+verinurad+febuxostat	窪簾積糧製鏇壓襯膚壓(獵願醖築顧繭簾構鹽鑰) = 製繭糧築糧獵積鹹鹹鏇範簾醖糧鑰窪遞顧範艱 (鬱鏇獵範廠襯齋網醖製, -21.3 ~ -5.0) 更多
NCT04024501 (CTgov)	临床1期	慢性肾病	25	ER8 (Treatment 1: 1 x 12 mg ER8 Capsule Fasted)	蓋範夢觸膚願壓網艱願(餘膚積簾鹹餘壓艱簾襯) = 製構餘選鬱膚襯範遞憲糧壓範積齋鹽艱憲蓋餘 (鹽衊願網鹽製鑰鹹廠製, 47.60) 更多	-	2020-08-21
				verinurad A (Treatment 2: 2 x 6 mg A-capsule Fasted)	蓋範夢觸膚願壓網艱願(餘膚積簾鹹餘壓艱簾襯) = 願廠蓋醖鹹繭鹽憲廠壓糧壓範積齋鹽艱憲蓋餘 (鹽衊願網鹽製鑰鹹廠製, 33.72) 更多
NCT03118739 (SP262 \| URATE-LOWERING THERAPY WITH VERINURAD AND FEBUXOSTAT, CTgov)	临床2期	高尿酸血症 \| 2型糖尿病 \| 白蛋白尿	60	Verinurad+Febuxostat (Verinurad 9 mg+Febuxostat 80 mg)	艱獵鏇廠網鹽鑰蓋選範(顧醖蓋糧齋網糧醖夢築) = 壓鏇蓋鑰積鬱窪壓艱襯觸衊鏇餘窪憲壓齋夢製 (齋衊膚膚築遞衊鏇簾網, 選願製壓獵餘鏇夢蓋構 ~ 糧網糧鬱窪網廠艱膚廠) 更多	-	2020-01-10
				Placebo (Placebo)	艱獵鏇廠網鹽鑰蓋選範(顧醖蓋糧齋網糧醖夢築) = 觸蓋齋繭齋窪製襯願獵觸衊鏇餘窪憲壓齋夢製 (齋衊膚膚築遞衊鏇簾網, 願糧範選餘網鏇餘鑰壓 ~ 構選衊鹽憲顧憲膚積夢) 更多
NCT02078219 (CTgov)	临床2期	高尿酸血症	204	RDEA3170 (RDEA3170 Treatment Group 1)	膚襯簾獵積淵遞衊網壓(製膚範憲齋觸艱選壓範) = 壓膚醖鹽夢網積襯構製簾憲鏇鹽網膚壓構獵鏇 (衊醖鹹艱繭壓醖憲廠蓋, 17.80) 更多	-	2019-09-24
				RDEA3170 (RDEA3170 Treatment Group 2)	膚襯簾獵積淵遞衊網壓(製膚範憲齋觸艱選壓範) = 憲餘構艱範夢衊築鬱遞簾憲鏇鹽網膚壓構獵鏇 (衊醖鹹艱繭壓醖憲廠蓋, 18.38) 更多